NCT04731675View on ClinicalTrials.gov

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

May 5, 2022

Study Completion Date

May 5, 2022

Conditions
Tenosynovial Giant Cell TumorPigmented Villonodular Synovitis (PVNS)
Interventions
BIOLOGICAL

AMB-05X

AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R

Trial Locations (6)

43201

AmMax Bio Clinical Site, Columbus

Unknown

AmMax Bio Clinical Site, Leiden

AmMax Bio Clinical Site, Warsaw

AmMax Bio Clinical Site, Dnipro

AmMax Bio Clinical Site, Kharkiv

AmMax Bio Clinical Site, Kyiv

Sponsors

Lead Sponsor

AmMax Bio, Inc.
All Listed Sponsors
lead

AmMax Bio, Inc.

INDUSTRY

NCT04731675 - An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee | Biotech Hunter | Biotech Hunter